Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Finished Goods (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Finished Goods for 2 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Finished Goods rose 128.29% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 128.29% increase, with the full-year FY2025 number at $2.0 million, up 128.29% from a year prior.
  • Finished Goods was $2.0 million for Q4 2025 at Day One Biopharmaceuticals, up from $1.1 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $2.0 million in Q4 2025 to a low of $873000.0 in Q4 2024.